register

News & Trends - Pharmaceuticals

MSD’s spinoff Organon to acquire medical device company for $240M

Health Industry Hub | April 7, 2021 |
[Total: 1    Average: 5/5]

Pharma News: MSD (known as Merck in United States and Canada) has entered a definitive agreement in which its intended spinoff Organon will acquire the commercial-stage medical device company Alydia Health for a total of up to $240 million.

Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum haemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.

The transaction is expected to close after Organon has spun off from MSD as a standalone publicly traded company late in the second quarter of this year.

“The acquisition aligns with Organon’s strategy to become a global leader in women’s health by focusing our product development on her unmet medical needs,” said Kevin Ali, CEO of Organon.

Digital & Innovation - Health Industry Hub Digital Series

“We believe that Organon’s strong global commercial footprint in reproductive health, in conjunction with Alydia’s rapidly growing commercial capabilities, will help enable growth of the Jada System, including potential expansion into Europe and other developed countries, as well as in the world’s least developed markets where Organon has significant experience creating affordable access,” he added.

“Alydia Health is thrilled to join Organon as we hold a similar vision to bring technology and therapeutic solutions to market that can improve outcomes for women in need across the globe,” said Rob Binney, CEO of Alydia Health.

“Our goal is to help make childbirth safer for more women. With critical gaps in maternal care, we believe this acquisition will potentially accelerate the delivery of the Jada System to more women and communities in need,” he said.

The Jada System is intended to provide control and treatment of abnormal postpartum uterine bleeding or haemorrhage when conservative management is warranted. The safety and effectiveness of the Jada System was evaluated in the PEARLE study, a prospective, single-arm, clinical trial, under an approved investigational device exemption from the U.S. Food and Drug Administration (FDA).


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]

More


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]

More


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]

More